This interactive seminar will examine the biochemistry and physiology of low dose naltrexone. In recent years, there have been some novel and significant findings on the off-label usage of naltrexone. Within a specific dosage window, low dose naltrexone (LDN) can act as an immunomodulator in multiple autoimmune diseases and malignant tumors as well as alleviate the symptoms of some mental disorders. The results of increasing studies indicate that LDN exerts its immunoregulatory activity by binding to opioid receptors in or on immune cells and tumor cells. These new discoveries indicate that LDN may become a promising immunomodulatory agent in the therapy for cancer and many immune-related diseases as well as chronic Lyme disease and cognitive decline.
This seminar begins with examining the role of inflammation and cognitive decline. It will then analyze the anti-inflammatory effects of low-dose naltrexone and its positive effects upon memory by investigating its role in the treatment of two known causes of memory loss: Lyme disease and Hashimoto’s thyroiditis.